ArticleCancer immunology, immunotherapy : CII2016

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Sung-Eun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.